Every material Form 8-K Citius Pharmaceuticals, Inc. has filed with the SEC since August 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Citius Pharmaceuticals said its majority-owned subsidiary, Citius Oncology, issued a press release on November 4, 2026, presenting health-related quality of life results from pivotal Study 302 of LYMPHIR in relapsed or refractory cutaneous T-cell lymphoma. The data were presented at the EORTC-CLTG 2026 Annual Meeting in Berlin, held October 8–10, 2026. The filing states the quality of life analyses were exploratory and descriptive, with no formal statistical comparisons, and it contains no financial results or guidance.
Responders (n=25) in the primary analysis set showed mean Skindex-29 Total Score changes from -5.38 to -13.69 points, where lower scores indicate better quality of life.
Responders' FACT-G Total Score change at end of treatment was +3.21, compared with -2.28 for non-responders.
Among 41 patients with a baseline itch score of 20 mm or greater, 13 (32%; 95% CI, 18.1–48.1) achieved a clinically meaningful itch improvement.
Citius Oncology is partnering with the Cutaneous Lymphoma Foundation on a Quality of Life Workshop scheduled for November 2026.
Citius Oncology, a majority-owned subsidiary of Citius Pharmaceuticals, reported preliminary, unaudited LYMPHIR unit sales for the fiscal fourth quarter ended September 30, 2026. Units purchased by U.S. wholesalers rose 120% from the prior quarter, and the number of institutions ordering the product grew, but the figures are unaudited and no revenue or profit amounts were disclosed, so the full financial picture will not be known until the annual report expected in December 2026.
792 units purchased by U.S. wholesalers in the three months ended September 30, 2026, up 120% from 360 units in the three months ended June 30, 2026.
950 LYMPHIR vials ordered by prescribing centers from wholesalers in the fiscal fourth quarter, compared with 926 in the fiscal third quarter.
54 institutions had ordered LYMPHIR as of the release date, up from 44 as of August 14, 2026.
Figures are preliminary and unaudited; complete fiscal fourth quarter and fiscal 2026 results are expected in December 2026 with the Form 10-K.
Citius Pharmaceuticals received a Nasdaq extension until February 8, 2027 to show its stock closes at or above $1.00 per share, a continued listing requirement. The filing says the extension has no effect on the current listing, but if compliance is not regained by that date, Nasdaq will issue a delisting notice and the company may appeal.
Nasdaq granted an extension to February 8, 2027 for the $1.00 per share bid price requirement under Rule 5550(a)(2)
Compliance requires a closing bid of $1.00 or more for at least ten consecutive business days before February 8, 2027
Common stock will continue trading on the Nasdaq Capital Market under CTXR for now
The company says there can be no assurance it will regain compliance
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Citius Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →